Anaptysbio (ANAB.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov11

TD Cowen Reiterates Buy Rating on AnaptysBio

09:03

Nov10

AnaptysBio Pauses Rosnilimab Clinical Trial for Ulcerative Colitis

14:00

Nov7

Wells Fargo Upgrades AnaptysBio Target Price to $81

19:20

Nov5

Anaptysbio released FY2025 9 Months Earnings on November 4, 2025 (EST), with actual revenue of USD 126.35 M and EPS of USD -2.1042

04:00

Anaptysbio released FY2025 Q3 earnings on November 4 (EST), actual revenue USD 76.32 M (forecast USD 21.84 M), actual EPS USD 0.52 (forecast USD -1.2499)

04:00

Nov4

AnaptysBio Reports Significant Growth in Q3 Collaboration Revenue

22:07

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 76.32 M, Net Income 15.11 M, EPS 0.52

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 22.26 M, Net Income -38.63 M, EPS -1.3408

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 27.77 M, Net Income -39.33 M, EPS -1.2834

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change